PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis.

Zhang Ying,Du Qi,Wang Chaoran,Hu Min, Wang Miao,Li Qin

Cancer investigation（2022）

引用 0|浏览13

暂无评分

摘要

PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC.

查看译文

关键词

PARP inhibitor,first-line,maintenance therapy,meta-analysis,ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要